Many current studies on the epigenetic modification of fibroblasts involve operative specimens obtained at the time of replacement joint surgery.
Animal models have shown that growth factors from fibroblasts can stimulate or inhibit epithelial proliferation, and that the genetic modification of fibroblasts can induce cancer [ 24, 25, 133].
CAFs can promote the tumorigenic conversion of epithelial cells, whereas fibroblasts derived from normal tissue suppress this transition [ 75], reinforcing the existence of molecular modification of fibroblasts induced by epithelial tumour cells.
The above described modifications of fibroblast properties observed throughout serial in vitro expansion may all more or less participate to the in vivo age-related changes of the skin.
In our work, the ubiquitous modification of a fibroblast cell-derived ECM with azides was achieved through metabolic oligosaccharide engineering by adding the azide-modified monosaccharide Ac4GalNAz (1,3,4,6-tetra-O-acetyl-N-azidoacetylgalactosamine 1,3,4,6-tetra-O-acetyl-N-azidoacetylgalactosamine 1,3,4,6-tetra-O-acetyl-N-azidoacetylgalactosamine 1,3,4,6-tetra-O-acetyl-N-azidoacetylgalactosamine 1,3,4,6-tetra-O-acetyl-N-azidoacetylgalactosamine 1,3,4,6-tetra-O-acetyl-N-azidoacetylgalactosamine
This study suggested the influence of Col-1 modification on the attachment of fibroblast cells around the Ti abutment.
Chromatin immunoprecipitation followed by real time PCR reveals late deposition of the repressive H3K27me3 histone modification at fibroblast marker gene promoters and fibroblast-enriched transcription factor promoters with a concomitant decrease in mRNA expression (Liu et al., 2016a).
These findings demonstrate the critical role of histone modifications in the development of fibroblast resistance to apoptosis in both a murine model and in patients with pulmonary fibrosis and suggest novel approaches to therapy for progressive fibroproliferative disorders.
Because pulmonary fibrosis typically develops at days 14 21 post-bleomycin exposure, the fibroblasts that we used in our experiments (taken from mice at day 21 post-bleomycin treatment) may be phenotypically different from those used in the study by Wallach-Dayan et al. and may illustrate the plasticity of histone modifications in fibroblasts during the evolution of fibrosis.
The results indicate also indicate that the surface modification does not influence the biocompatibility and cell attachment of fibroblast to the surface.
One mechanism that may account for the permanent hyperactive switch in fibroblasts is epigenetic modification of gene expression.
